Featured news from NHIVNA
HIV-related news from NAM
AbbVie pangenotypic combination cures almost all hard-to-treat people with HCV genotype 3
Keith Alcorn, 2016-11-16 11:50:00
AbbVie’s pangenotypic combination of glecaprevir and
pibrentasvir cured almost all of the hardest-to-treat genotype 3 patients –
those with cirrhosis and/or previous treatment experience – in a phase II
trial, and looks suitable for use as an 8-week regimen in genotypes 2, 4,5 and
6, according to results of studies presented at the 2016 AASLD Liver Meeting this
week in Boston.
AbbVie is developing the combination of glecepravir and pibrentasvir
(G/P) as a pangenotypic regimen for hepatitis C treatment, to be dosed as a
once-daily pill without ribavirin. AbbVie will seek licensing approval for the combination
in the United States and European Union within the next few months.
Glecaprevir (ABT-493) is a hepatitis C virus (HCV) NS3/4A protease inhibitor active against
all genotypes of hepatitis C. Pibrentasvir (ABT-530) is an NS5A inhibitor also
active against all genotypes of HCV. Both agents are active against common
variants that confer resistance to first-generation agents of their classes.
ABT-493 is more potent against genotype 3 than other HCV protease inhibitors,
including products being developed by Merck (grazoprevir) and Gilead (GS-9451),
and ABT-530 has demonstrated higher potency than most other NS5A inhibitors
across all genotypes.
Results of two phase II studies, in most-difficult-to-treat
people with genotype 3 and of an 8-week treatment course, were presented at Sunday
sessions of The Liver Meeting. Further data from phase III registrational
studies are also being presented at the meeting and are reported separately.